Latest research on Atomoxetine

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Latest findings

Collectively, the drug-placebo response curves presented here for each of the different reporters and the various dependent measures paint a consistent picture of the benefits of Atomoxetine. [source, 2005]
First, it is clear that Atomoxetine is superior to placebo in reducing total ADHD symptoms as well as individual symptom clusters, such as inattention and hyperactivity. [source, 2005]
For each of these measures, the drug-placebo response curve was always situated above the line of no effect, indicating that subjects were more likely to respond to Atomoxetine than to placebo over the entire range of possible criteria of responsiveness. [source, 2005]
In addition, it is clear that Atomoxetine targeted the core features of ADHD rather than only one of its most conspicuous features of inattention and hyperactivity, as AUCs across total, inattention, and hyperactivity change scores were quite similar. [source, 2005]
Second, responsiveness to Atomoxetine was reliably assessed by clinicians, investigators, and patients, as the AUCs for the various dependent measures varied little (0.58–0.61) across reporters. [source, 2005]
Third, Atomoxetine not only reduced the symptoms of ADHD, but prevented the worsening of these symptoms as well, a finding that has been seen for drug-placebo response curve analyses of other medications [5,10,11]. [source, 2005]
In contrast however, these prior drug-placebo response curve analyses have also revealed stronger effects of other medications on clinician-rated ADHD symptomatology, as evidenced by AUCs of 0.86 for Adderall [5,10,11], 0.89 for Methylphenidate [5,10,11], and 0.93 for Desipramine [5,10,11], as compared to the AUC of approximately 0.60 presently observed for Atomoxetine. [source, 2005]
In conclusion, we have extended the statistical results of Michelson et al. [3] by using drug-placebo response curves to describe the clinical significance of the efficacy of Atomoxetine in the treatment of ADHD among adults. [source, 2005]
Rather than collapsing individual responses into means or single rates of response, the drug-placebo response curve illustrates clinically meaningful details that often are lost in a standard analysis, such as the ability of Atomoxetine to improve outcome and prevent worsening throughout the full range of outcome scores. [source, 2005]
The present drug-placebo response analysis provided strong support for the efficacy of Atomoxetine relative to placebo for reducing inattention, hyperactivity, and total ADHD symptoms assessed by a variety of reporters, and for preventing the worsening of these symptoms. [source, 2005]